

# GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

## Company

2024/05/02 17:12:09



**Price**  
**65.30**  
USD

**Difference** ▲ **-0.32% (-0.21)**



## Contact Details

GILEAD SCIENCES INC. Tel: +1-650-574-3000  
 -- Fax: +1-650-522-5853  
 333 Lakeside Drive Web: <http://www.gilead.com>  
 94404 Foster City E-mail: -

## Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	16,085,000,000		14,443,000,000		14,772,000,000	
<b>Common stock capital</b>		1,000,000		1,000,000		1,000,000
<b>Fixed assets</b>	46,040,000,000		48,728,000,000		53,180,000,000	
<b>Equity capital of a company</b>		22,749,000,000		21,209,000,000		21,064,000,000
<b>Cash and cash equivalents</b>	6,085,000,000		5,412,000,000		5,338,000,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		11,280,000,000		11,237,000,000		11,610,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		28,096,000,000		30,725,000,000		35,278,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		2,773,000,000		5,095,000,000		5,254,000,000
<b>Total assets</b>	62,125,000,000	62,125,000,000	63,171,000,000	63,171,000,000	67,952,000,000	67,952,000,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	18,000	17,000	14,400
<b>Equity ratio</b>	36.48%	33.52%	30.99%
<b>Debt-equity ratio</b>	174.10%	198.29%	222.67%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	18.18%	21.47%	25.09%

# GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

## Income statement

	2023	2022	2021
Turnover	27,058,000,000	27,085,000,000	27,372,000,000
Net income	5,664,000,000	4,592,000,000	6,225,000,000
EBIT	6,936,818,000	6,303,566,000	8,666,586,000
Operating income before taxes	6,859,000,000	5,814,000,000	8,278,000,000
Cash Flow	8,006,000,000	9,072,000,000	11,384,000,000
Net interest income	-568,000,000	-935,000,000	-1,001,000,000
Research and development expenses	5,758,000,000	4,998,000,000	5,363,000,000
Income taxes	1,247,000,000	1,248,000,000	2,077,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,404,010	1,488,082	1,775,378

## Board of Directors

## Members of Management Board

Jacqueline Barton	Member of Board of Directors
Jeffrey Bluestone	Member of Board of Directors
Sandra Horning	Member of Board of Directors
Ted Love	Member of Board of Directors
Anthony Welters	Member of Board of Directors
Harish M. Manwani	Member of Board of Directors
Javier Rodriguez	Member of Board of Directors
Kelly Kramer	Member of Board of Directors
Kevin Lofton	Member of Board of Directors
Daniel O'Day	Chairman of Managing Board
Andrew Dickinson	Member of Executive Committee
Deborah H. Telman	Member of Executive Committee
Flavius Martin	Member of Executive Committee
Johanna Mercier	Member of Executive Committee
Jyoti Mehra	Member of Executive Committee
MD, PhD Merdad Parsey	Member of Executive Committee
Stacey Ma	Member of Executive Committee